Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

#8482;; the timing of the announcement of clinical results and potential regulatory filings by Baxter Healthcare for BAX 855; the timing of availability of topline overall survival data for the NKTR-102 BEACON study; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and app
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/h85dj3/pharmaceutical ) has ... by Packaging Type, by Raw Material, by Drug Delivery ... to 2020" report to their offering. ... estimated to reach above $80 Billion by 2020 ... a steady growth rate in the coming years. Drug ...
(Date:7/29/2015)... York , July 29, 2015 ... Transparency Market Research " Active Pharmaceutical Ingredients (API) Market ... Forecast 2014 - 2020 " the global active pharmaceutical ... 2013 and is anticipated to reach USD 185.9 billion ... the forecast period from 2014 to 2020. ...
(Date:7/29/2015)... Fla. , July 29, 2015 ... of Azelastine HCl Nasal Solution, 0.1%. The U.S. Food ... New Drug Application (ANDA), which is AB rated ... Azelastine hydrochloride nasal solution (nasal spray) is a ... 2015 IMS Health sales data.  Azelastine HCl Nasal ...
Breaking Medicine Technology:Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 2Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 3Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 2Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 3Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 4Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 5
(Date:7/29/2015)... ... 2015 , ... Today the nonprofit Alliance for Aging ... in Older Adults, that provides a comprehensive overview of the factors that drive ... care experts can improve patient compliance. , Although influenza, pneumococcal, tetanus, and shingles ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Join Luz Delia ... healthfulness. Gerber believes that Well-Being begins with understanding how the body actually works. A ... of healthfulness within. Guests will receive tips on how to forge this new relationship ...
(Date:7/29/2015)... ... 29, 2015 , ... Topical BioMedics, Inc., announces it has ... Healing Cream designated as the nonprofit’s natural pain reliever of choice.     , ... Duty Deaths (LODD) and the high rate of pain and injuries firefighters are ...
(Date:7/29/2015)... ... 29, 2015 , ... According to the Miami Herald on July ... mental health disorders. Acu-detox may begin taking off in the South Florida community as ... addiction. Although acupuncture is not a new practice, it is not widely used, but ...
(Date:7/29/2015)... ... July 29, 2015 , ... For the second year ... featured in the list of the 50 fastest growing companies in Jacksonville. This annual ... business community. On July 16th, a team of Vast Bridges staffers were on hand ...
Breaking Medicine News(10 mins):Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Pampering and Empowerment Abound at Final Event in Luz Delia Gerber’s Book Unveiling 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:Vast Bridges Continues Its Swift Growth 2
... , EDINA, Minn., Aug. 17 Backpacks can be a ... adolescents. As students prepare for school, the Minnesota Chiropractic Association (MCA) and ... , , The MCA and ASF are ... Does the backpack have two wide, padded shoulder ...
... , , , ... announces its donation of a fully furnished two bedroom apartment to ... families to stay for free while undergoing care at the medical ... availability, the managing partners of Presidential Towers felt that this was ...
... , , Webinars held with ... , HARRISBURG, Pa., Aug. 17 The Secretary ... for elementary and secondary schools in an effort to keep kids and staff ... important message for parents is that sick children should not go to school. ...
... SAN DIEGO, Aug. 17 MedVantx was recognized by Inc. ... fastest-growing of all U.S. companies with three-year growth of 7,898 percent. ... available in the September edition of the magazine. , , ... honor and marks an important milestone in the growth of our company," ...
... DENVER, Aug. 17, The American Humane Association today officially ... welfare professionals on how to incorporate therapy animals into sessions ... have witnessed violence. When children have suffered trauma, it is ... a therapy animal into the process can help a child ...
... say , MONDAY, Aug. 17 (HealthDay News) -- The first ... has been identified by U.S. researchers. , The new marker ... a T -- in a segment of DNA near the ... They found it by studying the DNA of 1,671 people ...
Cached Medicine News:Health News:It's Backpack Safety Time 2Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2Health News:Department of Health Releases Guidance on Novel H1N1 Influenza for Schools K-12 2Health News:Department of Health Releases Guidance on Novel H1N1 Influenza for Schools K-12 3Health News:MedVantx Named to Inc. 500 List of Fastest Growing Companies 2Health News:MedVantx Named to Inc. 500 List of Fastest Growing Companies 3Health News:American Humane Association Launches Innovative 'Therapy Animals Supporting Kids (TASK)(TM)' Program 2Health News:American Humane Association Launches Innovative 'Therapy Animals Supporting Kids (TASK)(TM)' Program 3Health News:Genetic Discovery May Improve Hepatitis C Treatment 2
... The standards set by the new SZ61 ... developed "Comfort View eyepiece design and the ... less fatiguing than ever before. The compact ... of field as well as clarity, detail, ...
... The series SV stereomicroscopes ... type. Thanks to their mature ... to the job in hand. ... users of demanding routine applications ...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
... Corr was designed to have the following ... specimens (vital sections, cell cultures, specimens with ... differences in cover glass thickness (0.14...0.18 mm) ... The correction collar can also be ...
Medicine Products: